Alan H Bryce, MD
Aggarwal R et al. PRESTO: A phase III, open-label study of androgen annihilation in patients (pts) with high-risk biochemically relapsed prostate cancer (AFT-19). ESMO 2022;Abstract LBA63.
Attard G et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: A meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet 2022;399(10323):447-60. Abstract
Maha Hussain, MD, FACP, FASCO
Armstrong AJ et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2022;40(15):1616-22. Abstract
Davis ID et al. Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). ASCO 2022;Abstract LBA5004.
Fizazi K et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): A multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet 2022;399(10336):1695-707. Abstract
Hussain M et al. Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) by disease volume and disease risk in the phase 3 ARASENS study. Genitourinary Cancers Symposium 2023;Abstract 15.
Smith MR et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 2022;386(12):1132-42. Abstract
Matthew R Smith, MD, PhD
Azhar F et al. Differential expression of PDL-1 and tumour-associated macrophages in N0 and N+ penile cancer. Genitourinary Cancers Symposium 2022;Abstract 12.
Clarke NW et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid 2022;1(9). Abstract
George DJ et al. Real-world prevalence of select homologous recombination repair (HRR) alterations in patients with metastatic castration-resistant prostate cancer (MCRPC). SUO 2022;Abstract 74.
Smith MR et al. CYCLONE 3: A phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk, metastatic, hormone-sensitive prostate cancer (mHSPC). Genitourinary Cancers Symposium 2023;Abstract TPS289.
Smith RE et al. Evaluation of outcomes in patients (pts) with stage 4 non-small cell lung cancer (NSCLC 4) harboring actionable oncogenic drivers (AOD) when treated prior to report of mutation without tyrosine kinase inhibitors (TKI): An Integra Connect Database (ICD) retrospective observational study. J Clin Oncol 2022;40(16):1530. Abstract
Emmanuel S Antonarakis, MD
Agarwal N et al. TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients with DDR gene-mutated, metastatic castration-sensitive prostate cancer (mCSPC). Genitourinary Cancers Symposium 2023;Abstract LBA17.
Agarwal N et al. Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. Future Oncol 2022;18(4):425-36. Abstract
Bryce AH et al. TRITON3: A phase 3 study of rucaparib vs physician’s choice of therapy in mCRPC associated with HRD. Prostate Cancer Foundation Scientific Retreat 2022;Novel Clinical Trial Updates.
Clarke NW et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid 2022;1(9). Abstract
Smith MR et al. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): A multicentre, open-label, phase 2 trial. Lancet Oncol 2022;23(3):362-73. Abstract
Zhuang T et al. Association of baseline inflammatory biomarkers with outcomes in penile squamous cell carcinoma (pSCC) treated with immune checkpoint inhibitors (ICI). Genitourinary Cancers Symposium 2022;Abstract 11.
Prof Karim Fizazi, MD, PhD
Fizazi K et al. Phase 1 results of the ODM-208 first-in-human phase 1-2 trial in patients with metastatic castration-resistant prostate cancer (CYPIDES). Genitourinary Cancers Symposium 2022;Abstract 18.
Heisbourg J-D et al. Leukocyte subtypes and myeloid derived suppressor cells as prognostic markers in metastatic castration resistant prostate cancer treated with cabazitaxel: A satellite study of the CABASTY phase III trial. Genitourinary Cancers Symposium 2023;Abstract 126.
Oudard S et al. Cabazitaxel every 2 weeks versus every 3 weeks in older patients with metastatic castration-resistant prostate cancer (mCRPC): The CABASTY randomized phase III trial. ESMO 2022;Abstract 1363MO.
Patel M et al. BTCRC-HN17-111, A phase 2 trial of ADT (goserelin) in combination with pembrolizumab for patients with advanced salivary gland tumors expressing androgen receptor (AR). Genitor 2022;Abstract e18091.